Evidence map›Paper›PMID 36379579›Full record

ArticleThe Journal of rheumatology2023

Long-Term Opioid Therapy Among Patients With Systemic Lupus Erythematosus in the Community: A Lupus Midwest Network (LUMEN) Study.

Gabriel Figueroa-Parra, Molly M Jeffery, Jesse Y Dabit, Baptiste Chevet, Maria O Valenzuela-Almada, Mehmet Hocaoglu, Shirley-Ann Osei-Onomah, Shaheen Kurani, Sebastian Vallejo, Sara J Achenbach and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 2 countries.

Gabriel Figueroa-ParraG. Figueroa-Parra, MD, J.Y. Dabit, MD, MS, M.O. Valenzuela-Almada, MD, M. Hocaoglu, MD, S.A. Osei-Onomah, MPH, S. Vallejo, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-6077-8899
Molly M JefferyM.M. Jeffery, PhD, Division of Health Care Delivery Research, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0003-3854-6810
Jesse Y DabitG. Figueroa-Parra, MD, J.Y. Dabit, MD, MS, M.O. Valenzuela-Almada, MD, M. Hocaoglu, MD, S.A. Osei-Onomah, MPH, S. Vallejo, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.
Baptiste ChevetB. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France.ORCID 0000-0002-9646-7603
Maria O Valenzuela-AlmadaG. Figueroa-Parra, MD, J.Y. Dabit, MD, MS, M.O. Valenzuela-Almada, MD, M. Hocaoglu, MD, S.A. Osei-Onomah, MPH, S. Vallejo, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.
Mehmet HocaogluG. Figueroa-Parra, MD, J.Y. Dabit, MD, MS, M.O. Valenzuela-Almada, MD, M. Hocaoglu, MD, S.A. Osei-Onomah, MPH, S. Vallejo, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.
Shirley-Ann Osei-OnomahG. Figueroa-Parra, MD, J.Y. Dabit, MD, MS, M.O. Valenzuela-Almada, MD, M. Hocaoglu, MD, S.A. Osei-Onomah, MPH, S. Vallejo, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.
Shaheen KuraniS. Kurani, PhD, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0003-2366-7505
Sebastian VallejoG. Figueroa-Parra, MD, J.Y. Dabit, MD, MS, M.O. Valenzuela-Almada, MD, M. Hocaoglu, MD, S.A. Osei-Onomah, MPH, S. Vallejo, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.
Sara J AchenbachS.J. Achenbach, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
W Michael HootenW.M. Hooten, MD, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-5645-6355
Kamil E BarbourK.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0003-0546-6742
Cynthia S CrowsonC.S. Crowson, PhD, Division of Rheumatology, Mayo Clinic, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-5847-7475
Alí Duarte-GarcíaA. Duarte-García, MD, MSc, Division of Rheumatology, Mayo Clinic, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. duarte.ali@mayo.edu.ORCID 0000-0003-1749-5719
American Cancer Society · US

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
Interdisciplinary Infrastructure for Aging Research: Rochester Epidemiology ProjectR33AG058738 · NIA · MAYO CLINIC ROCHESTER · PI LEBRASSEUR, NATHAN K, OLSON, JANET E · 2020 to 2022
$2.4M
Lupus Midwest Network (LUMEN)U01DP006491 · DP · MAYO CLINIC ROCHESTER · PI CROWSON, CYNTHIA S · 2019 to 2020
$1.8M
ACL HHS U01DP006491NCATS NIH HHS UL1 TR002377NCCDPHP CDC HHS U01 DP006491NCCDPHP CDC HHS U01 DP006703NIA NIH HHS R01 AG034676NIA NIH HHS R33 AG058738
6 · The paper itself

Abstract

objectiveThere is little information about the epidemiology and factors associated with opioid therapy in systemic lupus erythematosus (SLE). We aimed to assess the prevalence of opioid therapy and explore factors associated with long-term opioid therapy (LTOT) in patients with SLE.

methodsPatients with SLE were matched with controls without SLE in a population-based cohort on January 1, 2015. We captured demographics, manifestations of SLE, comorbidities (ie, fibromyalgia, mood disorders, osteoarthritis, chronic low back pain [CLBP], chronic kidney disease (CKD), avascular necrosis, osteoporosis, fragility fractures, and cancer), and the Area Deprivation Index (ADI). Opioid prescription data were used to assess the prevalence of LTOT, defined as contiguous prescriptions (gaps of < 30 days between prescriptions) and receiving opioid therapy for ≥ 90 days or ≥ 10 prescriptions before the index date.

resultsA total of 465 patients with SLE and 465 controls without SLE were included. In total, 13% of patients with SLE and 3% of controls without SLE were receiving opioid therapy (

conclusionPatients with SLE are more likely to receive LTOT than controls. Among patients with SLE, LTOT was associated with pericarditis and several comorbidities. However, LTOT was not associated with CKD despite the limited pain control options among these patients.

Indexed as

FibromyalgiaFractures, BoneLupus Erythematosus, SystemicPericarditisAnalgesics, OpioidHumansRetrospective StudiesAnalgesics, Opioidcomorbiditylong-term opioid therapyopioidspain managementsystemic lupus erythematosus

Identifiers

PMID36379579
PMCPMC10066823
OpenAlexW4309157297

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.